Risk of developing fibroadenoma with the use of cyclosporine A in renal transplant recipients

Ren Fail. 2005;27(6):721-5. doi: 10.1080/08860220500243197.

Abstract

To investigate the effect of cyclosporine A (Cyc A) on the development of fibroadenomas, 30 renal transplant patients and 20 chronic renal failure patients on dialysis were breast examined with ultrasonography and/or mammography. Of the renal transplant patients, 17 were receiving Cyc A-based combination therapy for immunosuppression. All patients were female with the age range of 29.7+/-9.2 years in the transplant group and 33.95+/-9.91 in the dialysis group. Eight of the 17 patients receiving Cyc A had fibroadenomas, 5 of them having bilateral lesions. None of the other patients, those on dialysis and on non-Cyc A combination therapy had fibroadenomas. A significant difference for fibroadenoma incidence in patients receiving Cyc A combination immunosuppression was found.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biopsy, Needle
  • Breast Neoplasms / chemically induced*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / pathology
  • Cross-Sectional Studies
  • Cyclosporine / adverse effects*
  • Cyclosporine / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Fibroadenoma / chemically induced*
  • Fibroadenoma / epidemiology
  • Fibroadenoma / pathology
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / methods
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods
  • Risk Assessment
  • Transplantation Immunology / physiology

Substances

  • Immunosuppressive Agents
  • Cyclosporine